Bocquier A. auteur aut IRD Cortaredona Sébastien auteur aut IRD Fressard L. auteur aut IRD Loulergue P. auteur aut IRD Raude Jocelyn auteur aut IRD Sultan A. auteur aut IRD Galtier F. auteur aut IRD Verger P. auteur aut IRD text journalArticle eng text/pdf reformatted digital access Background: Annual seasonal influenza vaccination (SIV) is recommended for people with diabetes, but their SIV rates remain far below public health targets. We aimed to identify temporal trajectories of SIV uptake over a 10-year period among French people with diabetes and describe their clinical characteristics. Methods: We identified patients with diabetes in 2006 among a permanent, representative sample of beneficiaries of the French National Health Insurance Fund. We followed them up over 10 seasons (2005/06-2015/16), using SIV reimbursement claims and group-based trajectory modelling to identify SIV trajectories and to study sociodemographic, clinical, and healthcare utilization characteristics associated with the trajectories. Results We identified six trajectories. Of the 15,766 patients included in the model, 4344 (28%) belonged to the "continuously vaccinated" trajectory and 4728 (30%) to the "never vaccinated" one. Two other trajectories showed a "progressive decrease" (2832, 18%) or sharp "postpandemic decrease" (1627, 10%) in uptake. The last two trajectories (totalling 2235 patients, 14%) showed an early or delayed "increase" in uptake. Compared to "continuously vaccinated" patients, those in the "progressively decreasing" trajectory were older and those in all other trajectories were younger with fewer comorbidities at inclusion. Worsening diabetes and comorbidities during follow-up were associated with the "increasing" trajectories. Conclusions Most patients with diabetes had been continuously vaccinated or never vaccinated and thus had stable SIV behaviours. Others adopted or abandoned SIV. These behaviour shifts might be due to increasing age, health events, or contextual factors (e.g., controversies about vaccine safety or efficacy). Healthcare professionals and stakeholders should develop tailored strategies that take each group's specificities into account. specialized Diabetes mellitus Influenza vaccines Cohort studies Administrative claims Healthcare FRANCE 052 056 19 art. 918 [8 p.] 2019 1471-2458 https://www.documentation.ird.fr/hor/fdi:010076247 10.1186/s12889-019-7209-z 1471-2458 [F B010076247] https://www.documentation.ird.fr/hor/fdi:010076247 https://horizon.documentation.ird.fr/exl-doc/pleins_textes/divers19-08/010076247.pdf IRD - Base Horizon / Pleins textes 2019-09-19 2025-02-24 fdi:010076247 fre